Clinical trials: Lupus Erythematosus
Lupus Nephritis
A Study of Telitacicept in Lupus Nephritis
The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with active lupus nephritis.
- Trial name
- NCT05680480
- Testing
- Telitacicept 240 mg, Telitacicept 160 mg
- Where
- 45 sites in China
- Volunteers
- 120 people
- Sponsor
- RemeGen Co., Ltd.
Fetal Growth Retardation
SLE Therapy Changes in Pregnancy and Relation to Pregnancy Outcome
to review the changes to SLE medications during pregnancy including adherence and non-adherence to the medications and correlate these to the pregnancy outcome and post-partum course of the disease.
- Trial name
- NCT05176041
- Testing
- Naser Al-Husban
- Volunteers
- 156 people
- Sponsor
- University of Jordan
Healthy, Lupus Nephritis
Functional MRI in Lupus Nephritis
The primary objectives of the study are as follows: To develop and optimize a renal functional magnetic resonance imaging (MRI) protocol consisting of Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI), Blood-Oxygen…
- Trial name
- NCT01731054
- Where
- 4 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Biogen
Lupus Erythematosus
Psycho-social Consequences of Systemic Lupus Erythematosus
this project will allow us to evaluate and understand the impact of SLE on the couple's life and its relational and affective components.
- Trial name
- NCT03913754
- Testing
- Psycho-social consequences of lupus erythematosus
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, leading to chronic inflammation and damage to organs such as the kidneys, lungs, muscles, nerves, or blood cells.
- Conditions
- Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis, Relapsed/Refractory Idiopathic Inflammatory Myopathies, Relapsed/Refractory sjögren's Syndrome
- Trial name
- NCT07361094
- Testing
- Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy
- Where
- China
- Sponsor
- Beijing Boren Hospital
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus in Gullah Health
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, multiple organ involvement, and diverse clinical symptoms and immunologic manifestations.
- Trial name
- SLEIGH (NCT00756769)
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Systemic Lupus Erythematosus
A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus
The primary objective of this study is to evaluate the long term safety and tolerability of repeated administration of subcutaneous (SC) CEP-33457 for injection every 4 weeks over 72 weeks (18 doses) in participants with systemic…
- Trial name
- NCT01240694
- Testing
- CEP-33457
- Where
- 85 sites in United States, Belgium and 9 more
- Volunteers
- 136 people
- Sponsor
- Cephalon, Inc.
Systemic Lupus Erythematosus
Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease
The primary objective of the study is to assess the dose response and the dose frequency of epratuzumab in patients with SLE.
- Trial name
- NCT00624351
- Testing
- Epratuzumab
- Where
- 53 sites in United States, Belgium and 9 more
- Volunteers
- 227 people
- Sponsor
- UCB Pharma
Autoimmune Diseases, Systemic Lupus Erythematosus
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA U CAR T cells in patients with autoimmune diseases. 60 patients are planned to be enrolled in the dose-escalation trial.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Sclerosis, Primary Sjögren Syndrome
- Trial name
- NCT07246096
- Testing
- anti-CD19/BCMA U CAR T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changhai Hospital
Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN)
Non Invasive Assessment of Subclinical Atherosclerosis and Cardiovascular Risk Using TYG Index in Lupus Nephritis
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by loss of immune tolerance, autoantibody production, immune complex deposition, and complement activation, resulting in widespread…
- Trial name
- NCT07719322
- Where
- Egypt
- Volunteers
- 156 people
- Sponsor
- Assiut University
Recurrent or Refractory Systemic Lupus Erythematosus, Recurrent or Refractory IgG4 Related Diseases
the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
This study is designed as a single arm, open label, single center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetic or pharmacodynamic characteristics of the investigational drug V001-BCMA in…
- Conditions
- Recurrent or Refractory Systemic Lupus Erythematosus, Recurrent or Refractory IgG4 Related Diseases, Recurrent or Refractory Systemic Sclerosis, Recurrent or Refractory Idiopathic Inflammatory Myopathy
- Trial name
- NCT07339540
- Testing
- V001-BCMA
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Tongji Hospital
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT05859997
- Testing
- BRL-301
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Bioray Laboratories
Membranous Nephropathy, Lupus Nephritis (LN)
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
The primary objectives of this clinical trial is to evaluate the safety and tolerability of HLX79 in combination with HLX01 versus placebo in combination with HLX01 in the treatment of glomerulonephritis.
- Trial name
- NCT07038382
- Where
- 17 sites in China
- Volunteers
- 24 people
- Sponsor
- Shanghai Henlius Biotech
Lupus Nephritis
Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis
The objective of this study is to assess the as efficacy of rituximab as induction therapy in membranous lupus nephritis. Safety and tolerability will additionally be assessed.
- Trial name
- NCT00908986
- Testing
- Rituximab
- Sponsor
- Northwell Health
Lupus Nephritis
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)
The purpose of this study is to characterize the safety and tolerability of ixazomib when administered as multiple oral doses at escalating dose levels in participants with lupus nephritis.
- Trial name
- NCT02176486
- Testing
- Ixazomib
- Where
- 35 sites in United States, France and 5 more
- Volunteers
- 12 people
- Sponsor
- Takeda
Lupus Nephritis
Association Between Neuropathy and Some Autoantibodies in Systemic Lupus Erythematosus (SLE) Patients
1. Frequency of peripheral neuropathy associated with lupus nephritis 2. Sensitivity and specificity of some biomarkers used in diagnosis and follow up of SLE with lupus nephritis and peripheral neuropathy
- Trial name
- NCT06610422
- Volunteers
- 159 people
- Sponsor
- Assiut University
SLE
Association of Serum Interleukin-33 Levels With Clinical Manifestations in Systemic Lupus Erythematosus
This is a case-control study investigating serum IL-33 levels and their association with clinical manifestations in systemic lupus erythematosus (SLE).
- Trial name
- NCT07149402
- Volunteers
- 150 people
- Sponsor
- Assiut University
System; Lupus Erythematosus
Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)
This protocol is part of an FDA Individual Patient Expanded Access IND. This study is to be conducted according to US and International Standards of Good Clinical Practice (FDA Title 21 part 312 and International Conference on…
- Trial name
- NCT04907175
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
Systemic Lupus Erythematosus
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
International trial to evaluate the biological activity and safety of cenerimod (ACT-334441) in systemic lupus erythematosus (SLE) patients.
- Trial name
- NCT02472795
- Testing
- Cenerimod
- Where
- 18 sites in United States, Belarus and 4 more
- Volunteers
- 105 people
- Sponsor
- Viatris Innovation GmbH
Systemic Lupus Erythematosus
Long-term Immunogenicity of a HPV Vaccine in SLE
To study the 5-year immunogenicity against a quadrivalent HPV vaccine in patients with SLE and healthy controls.
- Trial name
- NCT02477254
- Testing
- Vaccination
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Tuen Mun Hospital